DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Whether Alabama Medicaid covers Wegovy, Zepbound, Ozempic, or Mounjaro for weight loss and type 2 diabetes, prior authorization rules, and routes when coverage is denied.
T2D coverage requires documented A1C ≥7.5% on metformin for 3 months. Submit prior authorization through your prescriber, not directly. Approval decisions typically take 3-10 business days; expedited reviews for urgent cases process within 72 hours. Denials are appealable; first-round appeals succeed roughly 30-40% of the time when supporting documentation is thorough.
If Alabama Medicaid denies coverage, the practical routes are: (1) manufacturer cash-pay channels like NovoCare Direct (Wegovy at $499/month) and LillyDirect (Zepbound at $549/month), (2) compounded semaglutide or tirzepatide via telehealth (lower price but not FDA-approved; supply tightening after the May 2026 shortage resolution), or (3) charity care through patient assistance programs offered by Novo Nordisk and Eli Lilly for low-income patients.
Out-of-state telehealth providers must register; in-state license preferred. Major telehealth providers operating in Alabama include ro body, hims.
Limited weight-loss coverage. Most patients use cash-pay routes via LillyDirect or NovoCare.
Editorial summary, not legal or medical advice. State Medicaid policies change frequently. Confirm current status with Alabama Medicaid member services or your prescriber.